Rupert Sandbrink joined Lundbeck on 1 January 2022 as Senior Vice President, Head of Clinical Development.
Sandbrink will play a vital role in advancing Lundbeck’s clinical pipeline towards providing transformative medicines for people living with niche and rare brain diseases, the company states.
“I am looking forward to Rupert joining our R&D team. He brings strong leadership and broad expertise in all stages of Clinical Development. His impressive track record in successful drug development, in particular his experience in neuroimmunology and rare diseases, matched with our strong neuroscience dedicated clinical development organization, will enable us to further advance on our prioritized biology areas and to deliver innovative and life-changing therapies,” says Johan Luthman, Executive Vice President for Research & Development, Lundbeck.
Sandbrink is a Clinical Development leader in both larger pharmaceutical companies as well as small biotechnology entities. He brings more than 20 years of experience spanning all stages of clinical development, from First-in-Human and translational/experimental medicine studies to trials, regulatory submissions and product launches, including Medical Affairs, Regulatory Affairs and Pharmacovigilance.
Sandbrink grew up in Germany and received his MD from the University of Heidelberg. He also has a PhD in the Alzheimer’s disease research field. He is the author of more than 80 scientific publications.
“Lundbeck is a recognized premier neuroscience company with a long history and reputation for innovation. I’m thrilled to have the opportunity to be a part of Lundbeck’s R&D team and to continue the work to provide breakthrough treatments for people with brain diseases,” says Sandbrink.
Photo of Rupert Sandbrink: Vico Therapeutics